Regenxbio (NASDAQ:RGNX) Stock Rating Lowered by BidaskClub

Regenxbio (NASDAQ:RGNX) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a report released on Thursday, BidAskClub reports.

Other analysts have also recently issued research reports about the stock. Chardan Capital reiterated a “buy” rating and set a $150.00 price target (up previously from $145.00) on shares of Regenxbio in a research note on Tuesday, June 18th. Raymond James started coverage on shares of Regenxbio in a research note on Thursday, June 13th. They set an “outperform” rating for the company. Zacks Investment Research upgraded shares of Regenxbio from a “sell” rating to a “hold” rating in a research note on Thursday, July 25th. Morgan Stanley set a $84.00 price target on shares of Regenxbio and gave the stock a “buy” rating in a research note on Monday, July 15th. Finally, ValuEngine cut shares of Regenxbio from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 10th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $81.41.

NASDAQ:RGNX traded down $2.24 during trading hours on Thursday, reaching $41.21. 685,176 shares of the company’s stock were exchanged, compared to its average volume of 465,079. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of 17.32 and a beta of 0.71. The firm’s 50-day moving average is $48.86. The company has a quick ratio of 14.21, a current ratio of 14.21 and a debt-to-equity ratio of 0.01. Regenxbio has a 1-year low of $38.56 and a 1-year high of $83.45.

Regenxbio (NASDAQ:RGNX) last issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.89) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.85) by ($0.04). The business had revenue of $0.88 million for the quarter. Regenxbio had a negative return on equity of 9.90% and a negative net margin of 41.99%. Equities research analysts forecast that Regenxbio will post -2.4 earnings per share for the current fiscal year.

In other news, SVP Curran Simpson sold 18,000 shares of the firm’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $50.00, for a total value of $900,000.00. Following the completion of the sale, the senior vice president now owns 57,500 shares in the company, valued at approximately $2,875,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Kenneth T. Mills sold 15,000 shares of the firm’s stock in a transaction on Friday, July 19th. The stock was sold at an average price of $49.49, for a total transaction of $742,350.00. Following the completion of the sale, the insider now owns 261,000 shares of the company’s stock, valued at approximately $12,916,890. The disclosure for this sale can be found here. Insiders sold a total of 73,000 shares of company stock valued at $3,590,400 in the last 90 days. Company insiders own 13.80% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Mckinley Capital Management LLC Delaware lifted its stake in shares of Regenxbio by 51.8% in the 1st quarter. Mckinley Capital Management LLC Delaware now owns 888 shares of the biotechnology company’s stock worth $51,000 after acquiring an additional 303 shares during the period. Financial Gravity Wealth Inc. acquired a new stake in shares of Regenxbio in the 1st quarter worth $55,000. Berman Capital Advisors LLC lifted its stake in shares of Regenxbio by 41.6% in the 2nd quarter. Berman Capital Advisors LLC now owns 1,133 shares of the biotechnology company’s stock worth $58,000 after acquiring an additional 333 shares during the period. NEXT Financial Group Inc acquired a new stake in shares of Regenxbio in the 2nd quarter worth $69,000. Finally, SG3 Management LLC acquired a new stake in shares of Regenxbio in the 1st quarter worth $115,000. Institutional investors own 81.38% of the company’s stock.

Regenxbio Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Featured Article: What is a stock portfolio tracker?

Analyst Recommendations for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.